INTRODUCTION
============

*Filaggrin* (*FLG*) is a filament-associated protein that associates with keratins in epithelial cells and keratinocytes. *FLG* has also been designated as a natural moisturizing factor protein that contributes to the permeable barrier as an aggregated particle comprised of pro-*FLG*. *FLG* is expressed as a large precursor protein, pro-*FLG*. Pro-*FLG* is predominantly found in the granular layer of the epidermis. After dephosphorylation of pro-*FLG* and its proteolysis into several single *FLG* units, the units bind to intermediate keratin filaments and form a highly insoluble keratin matrix. This binding allows the attachment of cornified envelope proteins and lipids, which together form the stratum corneum that functions as the skin barrier. Therefore, pro-*FLG* and *FLG* expression levels have been established as keratinocyte differentiation markers; moreover, the expression of these proteins is essential for permeable barrier formation. Pro-*FLG* regulation is modulated by the transcription factors AP1 and peroxisome proliferator-activated receptor γ (PPARγ). Activation and binding of both transcription factors to the *FLG* promotor region initiates and increases the expression of pro-*FLG*. However, the mechanism by which *FLG* expression is regulated has not yet been fully elucidated[@B1][@B2][@B3][@B4].

Silent mating type information regulation 2 homolog (SIRT1) is one of the best-studied members of the class III histone deacetylase family. Members of this family are involved in many cellular process regulations, including apoptosis, differentiation, cellular senescence, endocrine signaling, glucose homeostasis, aging, and longevity. SIRT1 has various targets such as acetylated p53, p300, Ku70, forkhead box O transcription factors, PPARα, PPARγ, and PPARγ coactivator-1α[@B5][@B6][@B7]. SIRT1 promotes keratinocyte differentiation through the transcription factors PPARα, PPARγ, and CCAAT/enhancer-binding protein alpha[@B8]. Also, SIRT1 upregulates hypoxia inducible factor-1 (HIF-1) in a proportional relationship[@B9].

Adiponectin ameliorates insulin resistance, thereby improving glucose uptake and leading to more efficient energy expenditure. Adiponectin-mediated stimulation upregulates AMP-activated protein kinase (AMPK) activity, which plays a key role in the regulation of energy homeostasis and metabolic stress. The induction of AMPK stimulation suppresses essential enzymes involved in adenosine triphosphate (ATP)-consuming anabolic pathways, such as NAD^+^/NADPH, and increases the cellular ATP supply[@B10][@B11][@B12]. This regulation of energy expenditure is enhanced as SIRT1 deacetylation activity increases[@B13][@B14]. With respect to the modulation of these signal transduction pathways, adiponectin is a well-studied endocrinal agent that has been reported to show multiple beneficial effects in various tissues and organs[@B12][@B15][@B16]. However, few reports have focused on skin and/or keratinocytes, except for a few that have focused on proliferation and wound healing. In the context of the general signal transduction pathway of adiponectin stimulation, we hypothesized that adiponectin enhances *FLG* expression and/or regulation, thereby improving barrier permeability. A further aim of this study was to investigate the possibility of using adiponectin to ameliorate skin barrier-related diseases.

MATERIALS AND METHODS
=====================

Chemicals and reagents
----------------------

Full-length recombinant human adiponectin was obtained from Biobud (Seoungnam, Korea). Hydrogen peroxide (H~2~O~2~) was purchased from Junsei Chemicals (Tokyo, Japan). H~2~O~2~ was diluted with DDW to the designated concentration and aseptically filtered using a Millex GV 0.22 µm pore disk filter unit (Millipore, Carrigtwohill, Ireland). Anti-SIRT1 (Cat\# 8469) and anti-aryl hydrocarbon receptor nuclear translocator (ARNT, Cat\# 5537) antibodies were obtained from Cell Signaling Technology (Danvers, MA, USA), anti-*FLG* antibodies (Cat\# ab24584) were purchased from Abcam (Cambridge, UK), and anti-β-actin antibodies (Cat\# sc-47778) were obtained from Santa Cruz Biotechnology (Santa Cruz, CA, USA).

Cell culture
------------

Human normal epidermal keratinocytes (NHEKs) were obtained from Life Technologies (Carlsbad, CA, USA). Keratinocytes were maintained in EpiLife growth medium (Life Technologies) at 37℃ in a humidified atmosphere containing 5% CO~2~/95% air. EpiLife growth medium was refreshed every two days until cells were subconfluent or the desired cell population was obtained. All experiments were performed using cells from passages 3 to 4.

Immunoblot analysis
-------------------

Keratinocytes treated with the indicated compounds were washed twice in ice-cold phosphate-buffered saline (PBS). Cells were then lysed in lysis buffer and protein concentrations were determined using a bicinchoninic acid solution kit (Sigma-Aldrich, St. Louis, MO, USA). Proteins were separated on SDS-polyacrylamide/bis-acrylamide gels and transferred to polyvinylidene difluoride membranes (Millipore Co., Bedford, MA, USA). The membranes were blocked for 1 h in skim milk (BD Bioscience, Franklin lakes, NJ, USA). After blocking the membranes, they were rinsed with TBS-Tween 20 (TBS-T, 0.1% Tween 20). Next, the membranes were incubated with primary antibodies for 1 h at room temperature or overnight at 4℃. The membranes were then washed with TBS-T and then incubated for 1 h at room temperature with horseradish peroxidase-conjugated secondary antibodies. After extensive washing, immunoreactive bands were detected using Enhanced Chemi-Luminescence reagents (ATTO Corporation, Tokyo, Japan).

Cell viability
--------------

Cells were seeded in 48-well plates. After treatment with the indicated compounds, the medium was discarded. Cells were washed twice with PBS and then incubated with serum-free DMEM containing 1% 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT; Sigma-Aldrich Korea, Seoul, Korea). After termination of the reactions, the medium was discarded and 120 µl dimethyl sulfoxide (DMSO; Amresco, Cleveland, OH, USA) was added. The stained MTT was eluted and 100 µl was transferred to 96-well plates. The absorbance of each well at 570 nm was determined using a colorimetric plate reader.

Transfection with ARNT-targeting or SIRT1-targeting specific small interfering RNA
----------------------------------------------------------------------------------

siRNA targeting ARNT (s1615), siRNA targeting SIRT1 (HSS177403), and siRNA consisting of a scrambled sequence predicted not to induce specific degradation of any cellular message were purchased from Genolution (Seoul, Korea). For siRNA transfection, NHEKs were cultured in 60 mm^2^ dishes and incubated with G-fectin transfection reagent mix (Genolution) containing 20 nM siRNA. After a 48 h incubation period, the siRNA-transfected NHEKs were treated with Acrp30 for the indicated times. siRNA transfection did not affect cell viability, as demonstrated by visual inspection under a microscope (data not shown).

Statistical analysis
--------------------

Data are expressed as means±standard deviations. ANOVA with Bonferroni\'s correction was used to compare the means of two numeric values. Data analyses were performed with commercially available Prism 5 software (Graphpad, La Jolla, CA, USA). *p*-values \<0.05 were considered statistically significant.

RESULTS
=======

Cytotoxicity of adiponectin in NHEKs
------------------------------------

Human normal keratinocytes were treated with various concentrations of recombinant adiponectin for 24 h. Keratinocyte viability was determined by the MTT assay. Adiponectin-treated cells did not show any significant reduction in viability compared to control cells ([Fig. 1A](#F1){ref-type="fig"}).

Adiponectin stimulation increases *FLG* expression in a time-dependent and dose-dependent manner
------------------------------------------------------------------------------------------------

To test our hypothesis regarding the effect of Acrp30 on *FLG* expression, we treated keratinocytes with various concentrations of recombinant Acrp30 (0 to 20 µg/ml) for 24 h. Acrp30 treatment increased *FLG* and SIRT1 expression levels in a dose-dependent manner ([Fig. 1B](#F1){ref-type="fig"}). The optimal concentration of Acrp30 was found to be 10 µg/ml. In addition, keratinocytes were treated with 10 µg/ml of Acrp30 for various periods of time ranging from 0 to 48 h. Acrp30 stimulation upregulated the expression of SIRT1, ARNT, and *FLG* in a time-dependent manner. In particular, *FLG* exhibited a significant increase beginning at 12 h of Acrp30 treatment. SIRT1 exhibited increased expression from 4 h of Acrp30 stimulation, whereas ARNT exhibited increased expression from 12 h of Acrp30 stimulation ([Fig. 1C](#F1){ref-type="fig"}). Interestingly, the expression levels of SIRT1 and ARNT significantly decreased at 48 h of adiponectin stimulation. These data provide evidence that Acrp30 promotes *FLG* expression and possibly also SIRT1 and ARNT expression. These proteins could thus be involved in the signal transduction pathway by which *FLG* expression is regulated.

SIRT1 mediates Acrp30-induced *FLG* upregulation
------------------------------------------------

NHEKs were pretreated with the SIRT1-specific inhibitor sirtinol for 4 h to suppress the deacetylation activity of SIRT1, after which cells were treated with Acrp30 for 12 h or 24 h. Sirtinol treatment decreased the expression of *FLG* and suppressed Acrp30-mediated upregulation of *FLG*. Additionally, sirtinol downregulated ARNT expression and prevented the increase of SIRT1 expression induced by 12 h or 24 h of Acrp30 stimulation ([Fig. 2](#F2){ref-type="fig"}).

We next utilized SIRT1-targeting siRNA to investigate the role of SIRT1 in *FLG* expression. NHEKs were transfected with SIRT1-targeting siRNA or scrambled siRNA and incubated for 48 h, after which the cells were treated with Acrp30 for 24 h. Importantly, SIRT1 expression was successfully knocked down by SIRT1-targeting siRNA. Acrp30 stimulation did not alter *FLG* expression levels in SIRT1 siRNA-treated cells ([Fig. 3](#F3){ref-type="fig"}).

These results support our hypothesis that SIRT1 and ARNT play a role in the regulation of *FLG* expression.

Adiponectin upregulates ARNT in a SIRT1-dependent manner and regulates *FLG* expression
---------------------------------------------------------------------------------------

We next addressed whether Acrp30 affects ARNT and/or *FLG* expression in NHEKs, based on our finding that treatment of NHEKs with Acrp30 for 12 h resulted in a significant increase in ARNT expression ([Fig. 1B, C](#F1){ref-type="fig"}). We found that siRNA-mediated knockdown of SIRT1 significantly downregulated ARNT and suppressed *FLG* expression ([Fig. 3](#F3){ref-type="fig"}). siRNA-mediated knockdown of SIRT1 also blocked Acrp30-induced upregulation of ARNT.

Next, we silenced ARNT expression using ARNT-targeting siRNA. NHEKs were transfected with ARNT-targeting siRNA and then treated with 10 µg/ml Acrp30 for 24 h. ARNT expression was then analyzed by immunoblotting ([Fig. 4](#F4){ref-type="fig"}). Importantly, ARNT-targeting siRNA successfully silenced ARTN expression. ARNT siRNA-treated cells did not show any significant difference in *FLG* expression and did not exhibit Acrp30-mediated stimulation of *FLG* expression.

These data support our hypothesis regarding Acrp30 stimulation and SIRT1 signaling in *FLG* expression.

DISCUSSION
==========

Acrp30 is a well-established adipokine that is secreted from adipocytes and sebocytes and has beneficial effects on the whole somatic system[@B11][@B17][@B18][@B19]. Although Acrp30 has been predicted to positively affect skin function, few studies have tested this hypothesis. Here we tested the hypothesis that Acrp30 affects permeability of the skin barrier due to its stimulatory and signal transduction aspects.

The effect of Acrp30 on *FLG* expression in NHEKs has not previously been reported. We found that Acrp30 treatment upregulated *FLG* expression in a dose-dependent and time-dependent manner ([Fig. 1B, C](#F1){ref-type="fig"}) without significantly affecting NHEK viability ([Fig. 1A](#F1){ref-type="fig"}). We also observed dose-dependent and time-dependent increases in SIRT1 expression ([Fig. 1](#F1){ref-type="fig"}). Acrp30-mediated upregulation of SIRT1 has been reported in numerous studies and has become a well-established aspect of Acrp30 stimulation. We observed an increase of SIRT1 expression in NHEKs, which is consistent with previous reports. Additional studies have indicated that the expression and activation of SIRT1 in NHEKs promotes their differentiation. The expression and development of *FLG* in NHEKs is an essential part of differentiation, which is important in forming the permeability barrier. Therefore, the data presented above provide strong evidence in support of our hypothesis that *FLG* regulation is related to Acrp30 stimulation.

Recent studies have provided some evidence that *FLG* regulation is related to SIRT1. Specifically, the upregulation of SIRT1 has been shown to promote *FLG* expression and the silencing of SIRT1 has been shown to suppress *FLG*[@B4]. On the other hand, ARNT (also referred to as HIF-1β) has been identified as an *FLG* expression promotor related to the aryl hydrocarbon receptor[@B20][@B21]. Some studies have indicated that SIRT1 promotes HIF-1α expression, but none of these have investigated the relationship with ARNT[@B9].

Acrp30 stimulation induced ARNT upregulation, which follows the trend of SIRT1 expression ([Fig. 1](#F1){ref-type="fig"}). To investigate the relationship between Acrp30, SIRT1, and *FLG* regulation, NHEKs were treated with a SIRT1-specific inhibitor, sirtinol, for 12 h or 24 h. Pharmacological inhibition of SIRT1 suppressed *FLG* expression and also ARNT expression. Moreover, after pretreatment with sirtinol, the effects of Acrp30 stimulation were blocked, e.g., Acrp30 did not affect ARNT expression or *FLG* expression ([Fig. 2](#F2){ref-type="fig"}). This finding provides partial evidence for the role of SIRT1 in the regulation of *FLG* expression.

siRNA studies provided strong evidence for our hypothesis. In particular, NHEKs were treated with SIRT1-targeting siRNA for 48 h to knockdown SIRT1 expression. siRNA-mediated silencing of SIRT1 suppressed ARNT and *FLG* expression and blocked Acrp30 stimulation, whereas Acrp30 treatment of scrambled siRNA-treated cells resulted in upregulation of SIRT1, ARNT, and *FLG* ([Fig. 3](#F3){ref-type="fig"}). In addition, ARNT-targeting siRNA-treated cells exhibited reduced *FLG* expression and blocked Acrp30 stimulation, which is consistent with our SIRT1 siRNA data ([Fig. 4](#F4){ref-type="fig"}). Therefore, these results provide strong evidence that Acrp30-mediated upregulation of *FLG* is SIRT1-dependent. ARNT has been shown to initiate signal transduction by forming a complex with AhR[@B22]; however, we found that AhR-independent ARNT signaling is related to SIRT1 and triggers *FLG* regulation.

The data presented here support a relationship between SIRT1 and ARNT regulation. The novel SIRT1 activator resveratrol has been shown to upregulate SIRT1 and ARNT[@B23]. Although we did not notice any correlation with *FLG*, other studies have established relationships between ARNT and *FLG*[@B3][@B21].

SIRT1 has been shown to promote keratinocyte differentiation *in vitro*[@B8]. Other studies have established that genes related to keratinocyte differentiation, such as *Filaggrin* and involucrin, are regulated by ARNT[@B21][@B23][@B24]. In the present study, we showed that ARNT expression is also SIRT1-dependent.

In conclusion, our results support the hypothesis that Acrp30 regulates *FLG* expression through a SIRT1-dependent signal transduction pathway in human keratinocytes, thereby making a critical contribution to the permeability of the skin barrier. The mutation or silence of *FLG* had shown essential relationships with skin barrier disease[@B25]. Therefore, Acrp30 may thus be a useful adjunct in the treatment of skin barrier-related diseases such as atopic dermatitis or contact dermatitis.
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![Adiponectin stimulation increases *filaggrin* (*FLG*) expression in a time-dependent and dose-dependent manner without affecting the viability. Human normal epidermal keratinocytes (NHEKs) were treated with Acrp30 for 24 h at the indicated concentrations or with 10 µg/ml Acrp30 at the indicated time lines. (A) The MTT assay was performed to determine NHEK viability after Acrp30 treatment. (B, C) Cell lysates were generated with described lysis buffer and silent mating type information regulation 2 homolog (SIRT1), aryl hydrocarbon receptor nuclear translocator (ARNT), and *FLG* expression level was analyzed by immunoblotting. Representative results are shown from 3 independent experiments. NT: no treatment, O.D: optical density.](ad-29-407-g001){#F1}

![Silent mating type information regulation 2 homolog (SIRT1) inhibition blocks Acrp30-induced *filaggrin* (*FLG*) upregulation. Human normal epidermal keratinocytes were pretreated with 60 µM sirtinol for 4 h, after which they were treated with 10 µg/ml Acrp30 for 12 h (A) or 24 h (B). Cell lysates were generated with described lysis buffer and analyzed by immunoblotting. The protein amounts were quantified by comparison to β-actin. Immunoblotting was used to analyze the levels of SIRT1, aryl hydrocarbon receptor nuclear translocator (ARNT), and *FLG*. All blots shown are representative of 3 independent experiments. ^\*\*\*^*p*\<0.001 compared to the untreated group, ^\*\*\*\*^*p*\<0.0005 compared to the untreated group. NT: no treatment, ST: sirtinol.](ad-29-407-g002){#F2}

![siRNA-mediated silencing of silent mating type information regulation 2 homolog (SIRT1) blocks Acrp30 stimulation and *filaggrin* (*FLG*) regulation. Human normal epidermal keratinocytes were transfected with 20 nM of SIRT1-targeting siRNA or scrambled siRNA and incubated for 48 h. Next, the transfected cells were treated with 10 µg/ml Acrp30 for 24 h. Cell lysates were generated with described lysis buffer and analyzed by immunoblotting. The protein amounts were quantified by comparison to β-actin. Immunoblotting was used to analyze the levels of SIRT1, aryl hydrocarbon receptor nuclear translocator (ARNT), and *FLG*. All blots shown are representative of 3 independent experiments. ^\*\*^*p*\<0.05 compared to the untreated group,. ^\*\*\*^*p*\<0.001 compared to the untreated group, ^\*\*\*\*^*p* \<0.0005 compared to the untreated group.](ad-29-407-g003){#F3}

![siRNA-mediated knockdown of aryl hydrocarbon receptor nuclear translocator (ARNT) blocks Acrp30 stimulation and *filaggrin* (*FLG*) regulation. Human normal epidermal keratinocytes were transfected with 20 nM of ARNT-targeting siRNA or scrambled siRNA and incubated for 48 h. Next, the transfected cells were treated with 10 µg/ml Acrp30 for 24 h. Cell lysates were generated with described lysis buffer and analyzed by immunoblotting. The protein amounts were quantified by comparison to β-actin. Immunoblotting was used to analyze the levels of silent mating type information regulation 2 homolog (SIRT1), ARNT, and *FLG*. All blots shown are representative results of 3 independent experiments. ^\*\*\*^*p*\<0.001 compared to the untreated group.](ad-29-407-g004){#F4}
